American nutritional supplements maker Neurohacker Collective has partnered with ChromaDex to launch Qualia NAD+, a nicotinamide adenine dinucleotide (NAD+) supplement intended for optimising cellular health.

ChromaDex is a global bioscience firm focused on healthy ageing research and NAD+.

Qualia NAD+, which features ChromaDex’ patented nicotinamide riboside (NR) ingredient, Niagen, is intended to boost the level of NAD+ in ageing Americans.

Neurohacker Collective CEO James Schmachtenberger said: “Our science team was uniquely equipped to formulate a revolutionary NAD+ product because optimising NAD+ levels requires the type of complex nutritional science we’ve specialised in for nearly a decade.

“Qualia NAD+ provides consumers the type of deeply comprehensive NAD+ support that the market had been lacking.

“We also valued impeccable sourcing for each ingredient we selected. For example, we’re honoured to partner with ChromaDex to use their patented Niagen NR as it is an ingredient at the forefront of the NAD+ industry-leading in quality and clinical evidence.

“We used a similar vetting philosophy for every ingredient in the formula.”

The supplement offers Niacin, Niacinamide, and NR precursors along with 11 other ingredients shown to support additional aspects of NAD+ production, Neurohacker Collective said.

In a pilot study, the use of Qualia NAD+ led to 95% of participants rating their experience with the NAD+ supplement as good to excellent.

ChromaDex business development senior vice president Jason Campbell said: “Created with the highest scientific rigor and quality standards, our patented Niagen NR ingredient is the most efficient precursor available because it can cross the cell membrane directly.

“We look forward to this partnership with Neurohacker Collective as the unique Qualia NAD+ formulation will expand the positive effects of our precious Niagen to more people worldwide.”

Qualia NAD+ is already available on Neurohacker Collective’s website since early October. An expanded product launch is expected to start in additional channels soon.